NCT05208528View on ClinicalTrials.gov

Effect of the Probiotic ES1 and Its Inactivated Form (HT-ES1) Over Symptomatology Asociated With Allergic Rhinitis

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 23, 2022

Primary Completion Date

January 17, 2024

Study Completion Date

March 27, 2024

Conditions
Allergic Rhinitis
Interventions
DIETARY_SUPPLEMENT

ES1 group

Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.

DIETARY_SUPPLEMENT

HT-ES1 group

Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.

DIETARY_SUPPLEMENT

Control group

Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.

Trial Locations (1)

43204

Eurecat, Reus

All Listed Sponsors
collaborator

ADM-BIOPOLIS S.L.

UNKNOWN

lead

Fundació Eurecat

OTHER